DOT1L is a protein methyltransferase known to methylate lysine 79 of histone 3 (H3K79), an epigenetic mark associated with transcriptionally active genes. 1 Chromosomal translocations recurrent in leukemia result in oncogenic fusions between MLL and a variety of genes, such as AF4 or AF9, that recruit DOT1L to aberrant genomic loci, and transcriptional activation of leukemic genes. 2 Small molecule inhibitors of DOT1L activity can reverse the oncogenic reprogramming of MLL-rearranged leukemia, 3, 4 and the first-inclass DOT1L inhibitor pinometostat (EPZ-5676; Epizyme) has progressed to Phase I clinical trials for the treatment of pediatric patients with relapsed/refractory leukemias bearing a rearrangement of the MLL gene. 5 Most current DOT1L inhibitors, such as EPZ004777 and EPZ-5676, compete with the methyl donating cofactor S-adenosyl-L-methionine (SAM). These SAM analogues lock a conformationally dynamic loop of the enzyme into an inactive state. 6, 7 In a variation on this theme, recently reported structurally novel inhibitors of DOT1L also antagonize the formation of an enzymatically active state, but only partially occupy the cofactor site. 8, 9 Selective inhibition of DOT1L can also be achieved by functionalizing the adenosine ring of S-adenosyl-L-homocysteine (SAH), the reaction product of SAM ( Figure 1 ). Bromodeaza-SAH (Br-SAH) is a potent and selective inhibitor of DOT1L activity with a bromine atom that occupies a hydrophobic cavity specific to DOT1L, but this compound is inactive in cell based systems, probably due to poor cell penetration. 10 Modification of EPZ004777 by introduction of a bromine atom on the adenosine ring gave SGC0946 and both compounds selectively kill human cord blood cells transformed with an MLL-AF9 fusion oncogene. 7 However, the poor pharmacokinetic properties of EPZ004777 precluded conventional dosing methods for efficacy studies in a mouse xenograft model of MLL. 3 Nonclinical in vivo pharmacokinetics of EPZ-5676 in mouse, rat and dog showed moderate to high clearance and low oral bioavailability, 11 and so EPZ-5676 was administered by continuous intravenous infusion in the Phase I clinical trial. 5, 11 As part of our research efforts to discover new inhibitors of DOT1L activity with improved pharmacokinetic properties, we adopted a strategy to identify novel functional groups that would favourably exploit the hydrophobic cavity adjacent to the adenine binding site of SAH in DOT1L. In addition, we wished to avoid the use of heavy halogen atoms as they confer higher lipophilicity to drug molecules which tends to be detrimental to drug-like properties. In this Letter, we disclose cyano-deaza-SAH (19, CN-SAH) as a potent and selective inhibitor of DOT1L activity that incorporates a polar nitrile group which binds in this hydrophobic pocket.
Previously, a screen of a library of 3120 kinase inhibitors had identified 5-iodotubercidin (3, 5-ITC) as an inhibitor of DOT1L activity (IC50 18.2 M) which was subsequently optimised to Br-SAH (IC50 0.077 M).
We adopted a related approach where the tubercidin template (2) was investigated as a model system with the objective of transferring preferred structure-activity-relationships (SARs) into more relevant templates for potential use as biochemical and structural tools, chemical probes with cell activity, and ultimately to chemical leads suitable for convenient dosing in preclinical in vivo efficacy studies. d Yu et al. [7] ; e Yi et al. [13] .
The nucleoside target compounds were either purchased from commercial sources (1-6, 13-15) or prepared using short synthetic sequences (7-12, 16-18) as described in detail in the Supplementary
Material. The DOT1L inhibitory activity of target compounds 1-19 (Table 1) 
Figure 2. Design of CN-SAH (19).
Based on these results, we selected toyocamycin (5) 22 Reduction of the C6-Br by catalytic transfer hydrogenation gave 25 and then deprotection of the benzoates afforded toyocamycin (5). 21 Conversion of the 5'-OH to the corresponding 5'-chloride 26 activated the 5' position of the sugar ready for the introduction of the homocysteine moiety. This followed the procedure of Yu et al. 10 except that t-butyl Boc-L-homocysteinate (27) was used which greatly improved the efficiency of the reactions even with the additional step to simultaneously deprotect the homocysteine acid and amine groups. CN-SAH (19) was shown to be a potent inhibitor of DOT1L with an IC50 value of 26 nM ( Table 1) . To establish the binding mode, we solved the structure of CN-SAH in complex with DOT1L (2.3 Å, PDB code 5JUW). As expected, the structure is nearly identical to DOT1L in complex with SAM (PDB code 1NW3) and Br-SAH (PDB code 3SX0). The activation loop of DOT1L is folded on the cofactor mimetic, in a conformationally active state. The nitrogen atom of the 5-nitrile of CN-SAH occupies the hydrophobic pocket composed of V249, L224, P133, and F245 as previously exploited by the bromine of Br-SAH. CN-SAH (19) was confirmed to be a potent inhibitor of DOT1L (IC50 = 13 nM) by independent evaluation (Table 2 and Supplementary Material). In addition, CN-SAH was 17-times more potent than SAH against DOT1L which, like the bromine atom of Br-SAH, shows the nitrile group of CN-SAH better exploits the hydrophobic pocket of DOT1L. CN-SAH was then screened against a panel of representative protein lysine (PKMT), protein arginine (PRMT) and DNA (DNMT) methyltransferases to establish the selectivity profile (Table 2) . CN-SAH was inactive at concentrations up to 100 M against the PKMTs EZH2 (as part of PRC2 complex), SUV39H2 and SETD7 although there was very weak activity for G9a. CN-SAH showed inhibitory activity for both PRMT3 and the PRMT5 complex but with acceptable selectivity at 66-and 180-fold respectively. The selectivity of CN-SAH over these PRMTs is modestly improved when compared to BrSAH (both 30-fold) which reflects improved affinity for DOT1L rather than weaker activity for the PRMTs. CN-SAH was shown to be an inhibitor of DNMT1 with only 11-fold selectivity and would need to be improved.
In summary, we have designed and evaluated a number of new nucleoside derivatives as inhibitors of DOT1L activity. SARs established that DOT1L inhibition could be achieved through incorporation of polar groups and small heterocycles at the 5-position (5, 6, 12) or by the application of alternative nitrogenous bases (18) . Based on these results, CN-SAH (19) was identified as a potent and selective inhibitor of DOT1L activity where the polar 5-nitrile group was shown by crystallography to bind in the hydrophobic pocket of DOT1L. The next phase of these studies will be to develop CN-SAH into a chemical probe that is active in cell-based models and with good oral activity in rodent models of disease. 
